Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

HKSH Medical Group

Status: Completed

Conditions: Covid-19 Vaccine

Treatments: Biological: CoronaVac Vaccine; Biological: BNT162b2 Vaccine

Study type: Observational

Funder types: Industry

Identifiers

NCT04898946

Covid-19 Vaccine Antibody

Details and patient eligibility

About

Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported. A number of vaccines have been shown to be efficacious against symptomatic and severe infection by inducing neutralizing antibody (NAB) against spike protein of the SARS-CoV-2 virus. However, the duration of protection and longevity of antibody response is unknown.

Health care workers (HCWs) who are planning to receive COVID-19 vaccine will be recruited. The level of antibody against spike protein by different quantitative assays will also be serially measured .

Enrollment: 480 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Any staff, visiting doctor, nursing student of HKSH who are aged 18 or above
2. No contraindication for COVID-19 vaccination and plan to receive the intended dosages at the appropriate interval.
3. A baseline serology taken within 1 week before vaccination shows no evidence of recent infection.
4. No history of documented COVID-19 infection

Exclusion criteria

Trial design

480 participants in 2 patient groups

BNT162b2

Description:

Subjects who receive mRNA vaccine BNT162b2.

Treatment:

Biological: BNT162b2 Vaccine

CoronaVac

Description:

Subjects who receive inactivated vaccine, CoronaVac.

Treatment:

Biological: CoronaVac Vaccine